| Name | Ranirestat |
| Description | Ranirestat (AS-3201) is an orally active and potent aldose reductase (AR) inhibitor with neuroprotective properties that ameliorates peripheral nerve dysfunction in rats with advanced diabetic polyneuropathy.Ranirestat inhibits the inflammatory response of high glucose-exposed endothelial cells and may be useful for the study of diabetic sensory-motor polyneuropathy. |
| In vitro | Ranirestat concentration-dependently inhibits sorbitol accumulation in rat erythrocytes and sciatic nerves incubated in a high concentration (500 mg/dl) of glucose[1]. |
| In vivo | In approximately 12-week-old male STD-Wistar rats (260-290 g) injected with Streptozotocin (STZ), Ranirestat (0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg; oral administration, once daily, for 3 weeks) dose-dependently decreased the elevated sorbitol and fructose levels in the rat sciatic nerves without affecting blood glucose levels[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.76 mM), Sonication is recommended.
DMSO : 30 mg/mL (71.4 mM), Sonication is recommended.
|
| Keywords | Recombinant humanaldose reductase | Rat lens aldose reductase | Ranirestat | aldose reductase |
| Inhibitors Related | FH1 | Furaneol | Epalrestat | 2-Chloro-1-(4-fluorobenzyl)benzimidazole | Dicoumarol | 4-hydroxyphenyl acetate | Lapisteride | Alpha-Estradiol | Finasteride | Isoliquiritigenin | AKR1C1-IN-1 | Kopexil |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Diabetic Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
